Moderna CEO says that the COVID-19 current vaccines are not as effective as the South African Omicron variety.

Stephane Bancel said that CNBC’s Squawk Box has been informed by his company about the variant. He is trying to figure out what risk it presents to Americans.

He is concerned that Moderna’s COVID-19 vaccination against the virus may be less effective than the one he has now.

Last week’s variant is considered to be most dangerous and may allow the virus to escape vaccine protection.

Although it is not yet detected in the United States yet, officials from the health sector are already on alert for the possibility of another Covid-related surge. 

Moderna CEO Stephane Bancel (pictured) told CNBC's Squawk Box that his company believes its COVID-19 vaccine may have up to eight times less virus fighting antibodies against Omicron than other strains of the virus

Stephane Bancel from Moderna, the CEO (pictured), said to CNBC’s Squawk Box his company believed that COVID-19 may contain eight times more Omicron fighting antibodies than other viruses.

The COVID-19 vaccines work by attacking the virus's spike protein. Omicron is a rare strain that has more than 30 mutations of the protein, leading some experts to believe it can dodge vaccine protections. Pictured: A man receives a shot of a COVID-19 vaccine in El Monte, California, on November 17

COVID-19 vaccines attack the spike protein of the virus. Omicron, a rare strain with more than 30 variants of the protein makes it possible to bypass vaccine protections. Pictured: On November 17, a man received a COVID-19 shot in El Monte (California).

“There are 2 key points that we don’t yet know and will learn in.” [coming]Bancel stated, “Weeks]”.

One is vaccine efficacy. The vaccine efficacy of this variant will be affected by it. We’ll know in about two weeks.

Omicron, which was found for the first times last week in South Africa and believed to be from Botswana, has been discovered.

The sequence was detected in at least 77% of South Africans and in some who have recently left South Africa.

We believe in this [variant] is highly infectious… it seems to be much more infectious than Delta,’ Bancel said. 

Although not much information is available about this variant, experts fear it could evade vaccinations because of the many and different types mutations that it has.

Contrary to the other variants of Beta and Delta, Omicron mutations target the spike protein. Moderna’s vaccines for mRNA are not directed at this part.

There are over 30 variants of the spike protein in this variant, which is quite high compared to other varieties.

Bancel explained that it’s possible the effectiveness of all vaccines is decreasing because of the high level of mutation.

However, it can still take between two and six weeks for the company to fully understand how the vaccine interrelates with other vaccines. 

Bancel reported that the company might have an up-to-date version of their Covid jab in place for Americans in 60 to 90 days, if needed.

Moderna has begun testing an increased dose of Covid booster, as it was authorized for recently. The booster contains a lower amount than that used in the two-shot oringal regimen. 

The company has also been working on booster candidates that it had originally designed in fear of a vaccine-resistant variant. A Omicron-specific booster shot, however, is currently being rapidly tracked. 

The world remains in an uneasy waiting position as global health authorities continue to investigate this variant.

The United States will ban incoming flights to seven African countries beginning Monday.

It is still spreading around the globe, however.

The first countries to spot cases in last week’s outbreak were South Africa, Botswana, and Hong Kong.

Quickly, several European countries, including Austria, Belgium Czech Republic, Denmark and Germany all sequenced variants of the variant in the last few days.

Omicron cases in the United Kingdom were also discovered over the weekend.

Two Canadian cases of the variant were found to be sequenced in North America Sunday. It was a terrifying prospect for America.

Bancel claims that this variant is already spreading around the globe, even in places where there has been a travel ban. It will be soon detected everywhere.

He stated that he also believes it was already in all countries.

Omicron’s rise has also led many to call for more vaccine equity in the global marketplace. Some believe that new strains of Omicron can be avoided by a robust vaccination campaign.

Africa is the continent where this variant first appeared. Only six percent of Africans have been vaccinated with at least one COVID-19 vaccination, though some countries may have only partially vaccinated fewer than two percent.

Bancel stated that Moderna was working to close the vaccine gap but has encountered some difficulties.

“We currently have between 50-60 million doses (or more) of our vaccine available in our warehouse and ready to ship to people who are unable to receive vaccines or have customs issues.

Moderna is the second most widely used vaccine worldwide, trailing only the Pfizer BioNTech in America.

Representatives from both Pfizer and Moderna say that they will be able to update their current vaccines within the next 100 days if need be. Officials expect to learn more about the virus within the next two weeks (file photo)

Moderna representatives and Pfizer both claim that their existing vaccines will be updated within 100 days. Officials are expected to find out more about this virus within two weeks (file image).

According to the U.S. Centers for Disease Control and Prevention, Moderna has been given 173 million time and 71.5 millions people were fully vaccinated as of Monday morning.

Only 59 per cent of Americans are fully vaccinated, with just 70 percent having received at most one COVID-19 dose.

The CDC data shows that Pfizer’s vaccine was administered 264,000,000 times, thereby fully vaccinating 108 million persons.

Albert Bourla CEO at Pfizer told Squawk Box, “My company has acted quickly in response to Omicron’s threat.” 

Bourla announced that they had created their first DNA template on Friday, the first step in developing a vaccine. 

We would be able have a vaccine in under 100 days.

BioNTech is a German firm that has partnered with Pfizer in developing and distributing the vaccine. It reports it will soon have additional information about the variant and its response to it within two weeks.